The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation.
Marcus
F I
FI
Department of Internal Medicine, University of Arizona, Tucson.
D000813:Anilides / Q000009:adverse effects; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D016700:Encainide; D005424:Flecainide / Q000009:adverse effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D011405:Propafenone / Q000009:adverse effects
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D011405:Propafenone; D005424:Flecainide; D016700:Encainide